Business Wire

CA-ANDERSEN-GLOBAL

14.12.2022 13:17:37 CET | Business Wire | Press release

Share
Andersen and The University of San Francisco (USF) Expand Partnership to Create New Enterprise MBA Program Especially for Andersen Employees

Andersen — the leader in tax, valuation, financial advisory, and related consulting services — and The University of San Francisco (USF) have extended their partnership to create The Enterprise MBA program, in which eligible Andersen employees can earn an MBA in three to five years, fully-funded by Andersen on behalf of its employees. Modeled after the USF Masagung Graduate School of Management’s rigorous Part-Time MBA offering, the new program offers a standard MBA curriculum with courses tailored to address the specific professional development needs of Andersen employees in today’s complex, global business environment.

The new program is available to employees of Andersen member firms and collaborating firms, starting with U.S. employees and rolling out worldwide in 2023. Full- and part-time Andersen employees from senior associates to partners — regardless of tenure — are eligible for the program. Participating students must take three to four courses per year, delivered online and asynchronously, to complete the program requirements in five years. The first cohort of nearly 50 students started the pilot program in June 2022. USF welcomed 14 new Andersen students to the program in November 2022 and is targeting another 25-50 for January.

“Andersen strives to be the best professional services firm in the world and this new program is consistent with our dedication to continuous professional development and stewardship,” said Mark Vorsatz, CEO of Andersen. “To be the best in our industry, we have to attract and retain the best talent — that’s why we’re so committed to investing in our people. Working closely with the innovative educators at USF, we’ve built a customized program that reflects and enhances the work Andersen employees do on behalf of our clients every day. As the program grows, we expect it to be a unifying employee experience across our practice areas and global offices.”

Andersen’s offering is unique in the degree to which the firm was involved in course development, and the fact that the program is global in nature, fully funded by the firm, and does not have any kind of clawback, should employees enrolled in the program choose to leave the firm.

“Andersen’s culture is what keeps us together and what sets us apart,” continued Vorsatz. “Our investment in our people at all stages is just one component of how we are building and maintaining that culture.”

A Customized MBA to Meet Andersen’s Business Needs

Andersen and USF’s Masagung Graduate School of Management worked together to create a customized program, including content, delivery, modality, structure and timing, and even jointly creating a special elective class on the importance of company culture. In addition, in certain classes, Andersen senior staff can serve as adjunct professors to aid in instruction. Three trimesters of courses are offered each year: from early January to mid-to-late February; from early May to the end of August; and from early-November to mid-December. Given Andersen’s tax-centered business, program courses are offered outside of the busy tax seasons between March 1 and April 15 and between September 1 and October 15.

“This a truly unique and collaborative program and the close partnership between USF and Andersen sets a new standard for the future of corporate education,” said Otgo Erhemjamts, Dean of the School of Management at USF. “It demonstrates how educational institutions and companies can come together to address skill gaps and prepare organizations and their personnel for the rapidly evolving business world.”

Andersen and USF started their collaboration in 2014 when the organizations first partnered to provide Andersen personnel the opportunity to earn a Master of Laws in Taxation (LLM) or a Master of Legal Studies in Taxation (MLST) from the University of San Francisco School of Law. To date, more than 120 employees from 11 countries have graduated from those programs.

"The University of San Francisco, founded by the Jesuits in 1855, has long worked with the business community in and beyond the City to strengthen their talent pool,” stated USF President Rev. Paul J. Fitzgerald, S.J. “Our work with Andersen has been a terrific iteration of this work. The alignment of our cultures makes this excellent teaching/learning experience possible. We are especially grateful to Mr. Vorsatz for envisioning this dynamic partnership."

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 13,000 professionals worldwide and a presence in over 390 locations through its member firms and collaborating firms.

About the USF School of Management

Founded in 1925, University of San Francisco’s School of Management is on the forefront of educating the next generation of conscious, mindful business leaders. Each year those students join the over 40,000 School of Management alumni around the world to create ethical and innovative change in the private, public, and non-profit management sectors. The School of Management is accredited by the Western Association of Schools and Colleges Senior College and University Commission (WSCUC) and the Association to Advance Collegiate Schools of Business (AACSB).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005400/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye